NNRTI + FTC/TDF + Stribild
Phase 3Completed 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Acquired Immunodeficiency Syndrome
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Trial Timeline
Dec 1, 2011 โ Dec 1, 2014
NCT ID
NCT01495702About NNRTI + FTC/TDF + Stribild
NNRTI + FTC/TDF + Stribild is a phase 3 stage product being developed by Gilead Sciences for Acquired Immunodeficiency Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01495702. Target conditions include Acquired Immunodeficiency Syndrome, HIV Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01495702 | Phase 3 | Completed |
Competing Products
20 competing products in Acquired Immunodeficiency Syndrome